{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:36:38Z","timestamp":1793140598133,"version":"4.5.0"},"reference-count":35,"publisher":"IOP Publishing","issue":"20","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/iop-standard\/v1"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"Italian National Institute for Nuclear Physics","award":["CUPRUM-TTD research program (2023-2025)"],"award-info":[{"award-number":["CUPRUM-TTD research program (2023-2025)"]}]},{"DOI":"10.13039\/501100004493","name":"International Atomic Energy Agency","doi-asserted-by":"crossref","award":["CRP F-22078"],"award-info":[{"award-number":["CRP F-22078"]}],"id":[{"id":"10.13039\/501100004493","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["5x1000 (2019) DECURTA"],"award-info":[{"award-number":["5x1000 (2019) DECURTA"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Phys. Med. Biol."],"published-print":{"date-parts":[[2025,10,19]]},"abstract":"Abstract<\/jats:title>\n \n Objective.<\/jats:italic> The aim of this study was to evaluate the impact of the nuclear properties of six \u03b2<\/jats:italic>\n \u2212<\/jats:sup>-emitting radionuclides (47<\/jats:sup>Sc, 67<\/jats:sup>Cu, 111<\/jats:sup>Ag, 161<\/jats:sup>Tb, 177<\/jats:sup>Lu, and 188<\/jats:sup>Re) on the dosimetric outcomes of two tumour-targeting radiopharmaceuticals (RPs), with distinct pharmacokinetics: the peptide DOTA-folate conjugate cm09 and the monoclonal antibody HuM195. The study specifically focused on assessing the radiation-absorbed doses in organs and tumours, as well as comparing the efficacy and safety of the twelve RPs for targeted radionuclide therapy (TRT). Approach.<\/jats:italic> Murine biodistribution data for both RPs were scaled to adult human models to determine biological residence times and the number of disintegrations in source organs and tumours. Dosimetric estimations were performed using OLINDA and MIRDCell software, considering different tumour sizes and organ-specific radiation exposure for both male and female phantoms. Main results.<\/jats:italic> Significant differences in organ and tumour dosimetry were found across the considered radionuclides and tumour-targeting agents, attributable to the nuclear properties of the radionuclides and the RP pharmacokinetics. PFP-HuM195 labelled with 161<\/jats:sup>Tb and 111<\/jats:sup>Ag demonstrated efficient dose delivery to tumour from 1\u201310 mm, but also higher organ-absorbed doses per unit of injected activity than other labelling radionuclides. Cm09 exhibited less variability in tumour absorbed dose as the labelling radionuclide varied, but also produced much higher kidney absorbed doses than PFP-HuM195. Normalising to the same tumour absorbed dose showed that 177<\/jats:sup>Lu and 161<\/jats:sup>Tb are the safer options for treating small tumours (2.7\u201312.4 mm) with both RPs. These results demonstrate that the choice of radionuclide has a significant impact on both therapeutic efficacy and organ safety. Significance.<\/jats:italic> This research demonstrates that selecting the appropriate radionuclide for TRT can optimise therapeutic outcomes while minimising radiation exposure to healthy tissues. The findings contribute to advancing personalised TRT approaches by considering RP-specific pharmacokinetics and radionuclide characteristics, paving the way for more effective cancer treatments.<\/jats:p>","DOI":"10.1088\/1361-6560\/ae07a2","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:54:31Z","timestamp":1758063271000},"page":"205002","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of the impact of the nuclear properties of \u03b2<\/i>\n \u2212<\/sup>-emitting radionuclides on the dosimetry of two radiopharmaceuticals with distinct pharmacokinetics"],"prefix":"10.1088","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-370X","authenticated-orcid":true,"given":"Laura De","family":"Nardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3045-2721","authenticated-orcid":true,"given":"Samuele","family":"De Zan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J H","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0296-7605","authenticated-orcid":true,"given":"Gulliermina","family":"Ferro-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Dadachova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-3616","authenticated-orcid":true,"given":"Laura","family":"Mel\u00e9ndez-Alafort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"pmbae07a2bib1","doi-asserted-by":"publisher","first-page":"50000","DOI":"10.1021\/acsomega.4c09450","type":"journal-article","article-title":"In vitro and in vivo comparison of random versus site-specific conjugation of bifunctional chelating agents to the CD33-Binding antibody for use in alpha- and beta-radioimmunotherapy","volume":"9","author":"Allen","year":"2024","journal-title":"ACS Omega"},{"key":"pmbae07a2bib2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","type":"journal-article","article-title":"Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"pmbae07a2bib3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40658-022-00487-7","type":"journal-article","article-title":"Comparison of image quality and spatial resolution between 18F, 68Ga, and 64Cu phantom measurements using a digital Biograph Vision PET\/CT","volume":"9","author":"Braune","year":"2022","journal-title":"EJNMMI Phys."},{"key":"pmbae07a2bib4","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","type":"journal-article","article-title":"Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade","volume":"23","author":"Cri\u0219an","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"pmbae07a2bib5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.icrp.2008.10.004","type":"journal-article","article-title":"ICRP publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann. ICRP"},{"key":"pmbae07a2bib6","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2967\/jnumed.123.266171","type":"journal-article","article-title":"61Cu-labeled radiotracers: alternative or choice?","volume":"64","author":"Fani","year":"2023","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","type":"journal-article","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"pmbae07a2bib8","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","type":"journal-article","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"pmbae07a2bib9","first-page":"5","type":"journal-article","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP publication 89","volume":"32","author":"ICRP Publication 89","year":"2002","journal-title":"Ann. ICRP"},{"key":"pmbae07a2bib10","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2967\/jnumed.123.267238","type":"journal-article","article-title":"MIRD pamphlet no. 31: MIRDcell V4\u2014artificial intelligence tools to formulate optimized radiopharmaceutical cocktails for therapy","volume":"65","author":"Katugampola","year":"2024","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2967\/jnumed.121.263253","type":"journal-article","article-title":"MIRD pamphlet no. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling","volume":"63","author":"Katugampola","year":"2022","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/828329","type":"journal-article","article-title":"Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma","volume":"2013","author":"Klein","year":"2013","journal-title":"J. Skin Cancer"},{"key":"pmbae07a2bib13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0378-5173(99)00054-X","type":"journal-article","article-title":"Labeling peptides with rhenium-188","volume":"182","author":"Mel\u00e9ndez-Alafort","year":"1999","journal-title":"Int. J. Pharm."},{"key":"pmbae07a2bib14","first-page":"1649","type":"journal-article","article-title":"Development of a five-compartmental model and software for pharmacokinetic studies","volume":"70","author":"Melendez-Alafort","year":"2017","journal-title":"C. R. Acad. Bulg. Sci."},{"key":"pmbae07a2bib15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/molecules27051501","type":"journal-article","article-title":"67Cu production capabilities: a mini review","volume":"27","author":"Mou","year":"2022","journal-title":"Molecules"},{"key":"pmbae07a2bib16","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180074","type":"journal-article","article-title":"Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application","volume":"91","author":"M\u00fcller","year":"2018","journal-title":"Br. J. Radiol."},{"key":"pmbae07a2bib17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","type":"journal-article","article-title":"Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"pmbae07a2bib18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2967\/jnumed.112.107235","type":"journal-article","article-title":"DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice","volume":"54","author":"M\u00fcller","year":"2013","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/C3CS60304K","type":"journal-article","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"pmbae07a2bib20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10967-018-6238-x","type":"journal-article","article-title":"New developments in the production of theranostic pairs of radionuclides","volume":"318","author":"Qaim","year":"2018","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"pmbae07a2bib21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.apradiso.2008.09.011","type":"journal-article","article-title":"Evaluation of two methods for concentrating perrhenate (188Re) eluates obtained from 188W\u2013188Re generator","volume":"67","author":"Sarkar","year":"2009","journal-title":"Appl. Radiat. Isot."},{"key":"pmbae07a2bib22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","type":"journal-article","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"pmbae07a2bib23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/ph16101460","type":"journal-article","article-title":"Radiometals in imaging and therapy: highlighting two decades of research","volume":"16","author":"Sharma","year":"2023","journal-title":"Pharmaceuticals"},{"key":"pmbae07a2bib24","first-page":"37S","type":"journal-article","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/pharmaceutics11080424","type":"journal-article","article-title":"Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: preclinical investigations","volume":"11","author":"Siwowska","year":"2019","journal-title":"Pharmaceutics"},{"key":"pmbae07a2bib26","article-title":"Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose","author":"Sparks","year":"1999","type":"journal-article"},{"key":"pmbae07a2bib27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/HP.0000000000001682","type":"journal-article","article-title":"OLINDA\/EXM 2\u2014The Next-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine","volume":"124","author":"Stabin","year":"2023","journal-title":"Health Phys."},{"key":"pmbae07a2bib28","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/molecules27175429","type":"journal-article","article-title":"Radionuclides for targeted therapy: physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"key":"pmbae07a2bib29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/02611929221118001","type":"journal-article","article-title":"A history of regulatory animal testing: what can we learn?","volume":"50","author":"Swaters","year":"2022","journal-title":"Altern. Lab. Anim."},{"key":"pmbae07a2bib30","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.2174\/092986710791859397","type":"journal-article","article-title":"Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets","volume":"17","author":"Tolmachev","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"pmbae07a2bib31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/ph16070929","type":"journal-article","article-title":"Lights and shadows on the sourcing of silver radioisotopes for targeted imaging and therapy of cancer: production routes and separation methods","volume":"16","author":"Tosato","year":"2023","journal-title":"Pharmaceuticals"},{"key":"pmbae07a2bib32","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3390\/molecules27165283","type":"journal-article","article-title":"Rhenium radioisotopes for medicine, a focus on production and applications","volume":"27","author":"Uccelli","year":"2022","journal-title":"Molecules"},{"key":"pmbae07a2bib33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.2967\/jnumed.113.131037","type":"journal-article","article-title":"MIRD pamphlet no. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations in collaboration with the SNMMI MIRD committee","volume":"55","author":"Vaziri","year":"2014","journal-title":"J. Nucl. Med."},{"key":"pmbae07a2bib34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00259-021-05392-2","type":"journal-article","article-title":"Challenges and future options for the production of lutetium-177","volume":"48","author":"Vogel","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"pmbae07a2bib35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","type":"journal-article","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Physics in Medicine & Biology"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:19:03Z","timestamp":1759828743000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae07a2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":35,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,10,19]]}},"URL":"https:\/\/doi.org\/10.1088\/1361-6560\/ae07a2","relation":{},"ISSN":["0031-9155","1361-6560"],"issn-type":[{"value":"0031-9155","type":"print"},{"value":"1361-6560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"Assessment of the impact of the nuclear properties of \u03b2\n \u2212-emitting radionuclides on the dosimetry of two radiopharmaceuticals with distinct pharmacokinetics","name":"article_title","label":"Article Title"},{"value":"Physics in Medicine & Biology","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2025 Institute of Physics and Engineering in Medicine. All rights, including for text and data mining, AI training, and similar technologies, are reserved.","name":"copyright_information","label":"Copyright Information"},{"value":"2025-06-20","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-09-16","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-10-07","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}